arfolitixorin + fluorouracil + oxaliplatin + bevacizumab

This is a **combination regimen** consisting of four drugs: **arfolitixorin** (a novel folate-based biomodulator that enhances the efficacy of fluoropyrimidines), **fluorouracil** (a pyrimidine analog antimetabolite inhibiting thymidylate synthase, disrupting DNA synthesis), **oxaliplatin** (a platinum-based chemotherapeutic causing DNA crosslinking and apoptosis), and **bevacizumab** (a humanized monoclonal antibody targeting vascular endothelial growth factor A, inhibiting angiogenesis). This regimen is being investigated in the treatment of colorectal cancer, especially as a potential first-line therapy for metastatic colorectal cancer, aiming to improve chemotherapy efficacy and outcomes over standard regimens. Arfolitixorin is intended to optimize the activity of fluorouracil by providing a more effective folate substrate, while bevacizumab targets tumor angiogenesis. The combination seeks to leverage synergistic effects on cytotoxicity and tumor vascular suppression.